-- ENMD-2076 is an oral selective kinase inhibitor with a unique kinase
profile, including antiproliferative activity and inhibition of
angiogenesis. ENMD-2076 has demonstrated potent antitumor activity as a
single agent in multiple preclinical models, including tumor regression
in breast, colon, and leukemia models without cardiovascular effects.
ENMD-2076 is a unique-in-class compound that inhibits both Aurora A and
growth factor receptors critical to angiogenesis.
-- EntreMed's IND has been accepted by the FDA and a Phase 1 study in
solid tumors is expected to enroll patients in early 2Q08. EntreMed has
been selected for an oral presentation on ENMD-2076 during the American
Association for Cancer Research's "Drugs on the Horizon" symposium to
be held during the AACR annual meeting in April. ENMD-2076 milestones
for 2008 include initiating a Phase 1 trial in solid tumors (1Q08);
initiating a Phase 1 trial in hematological tumors (3Q08/4Q08); and
entering into a development alliance (2H08/1H09).
-- EntreMed plans to discontinue development of 2ME2 (Panzem(R) NCD) for
oncology. Modest antitumor activity has been shown across most of the
clinical studies, yet there is not a clear development path that would
narrow the indications for larger randomized studies. Additional trial
costs, the high doses required for use in oncology, and
manufacturing/process development expenditures would together require
the commitment of a disproportionate amount of resources and limit
clinical development efforts on the remainder of the pipeline. Patients
still on clinical oncology trials, however, will continue to receive
-- EntreMed plans to move 2ME2 forward in rheumatoid arthritis based on
the knowledge gained from the oncolo
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved